1. Home
  2. GILT vs AMLX Comparison

GILT vs AMLX Comparison

Compare GILT & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gilat Satellite Networks Ltd.

GILT

Gilat Satellite Networks Ltd.

HOLD

Current Price

$15.61

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Amylyx Pharmaceuticals Inc.

AMLX

Amylyx Pharmaceuticals Inc.

HOLD

Current Price

$13.62

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GILT
AMLX
Founded
1987
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
GILT
AMLX
Price
$15.61
$13.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$19.00
$21.56
AVG Volume (30 Days)
868.4K
992.4K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
65.46
EPS
N/A
N/A
Revenue
N/A
$380,786,000.00
Revenue This Year
$15.06
N/A
Revenue Next Year
$11.72
N/A
P/E Ratio
$42.82
N/A
Revenue Growth
N/A
1612.94
52 Week Low
$5.46
$4.64
52 Week High
$20.99
$18.61

Technical Indicators

Market Signals
Indicator
GILT
AMLX
Relative Strength Index (RSI) 41.86 39.29
Support Level $13.38 $13.36
Resistance Level $18.84 $15.37
Average True Range (ATR) 1.11 0.79
MACD -0.38 -0.17
Stochastic Oscillator 11.00 26.44

Price Performance

Historical Comparison
GILT
AMLX

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.

About AMLX Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Share on Social Networks: